BOSTON - NodThera, a biotech firm engaged in the development of treatments for chronic inflammatory diseases, today announced the appointment of Dr. Thomas Jaecklin as Chief Medical Officer (CMO). Dr. Jaecklin, with over two decades of experience in drug development across various therapeutic areas, steps into this role effective immediately.
Dr. Jaecklin's career includes leadership positions in several prominent biopharmaceutical companies. Most recently, he was the Vice President at Galapagos (NASDAQ:GLPG) NV (Euronext & NASDAQ: GLPG), where he led the Small Molecule Portfolio. His tenure at Galapagos was marked by several successful regulatory submissions and approvals. Before that, as Senior Vice President at Mirum Pharmaceuticals (NASDAQ: NASDAQ:MIRM), he was instrumental in securing the approval of Livmarli® for market release.
The CEO of NodThera, Alan Watt, expressed enthusiasm about Dr. Jaecklin joining the team, saying, "We are delighted to welcome Thomas to the NodThera team, with his wealth of sector experience and successful execution of drug development programs across multiple therapeutic areas. These will be critical to us delivering our vision of a paradigm shift in the treatment of disease through the selective modulation of the NLRP3 inflammasome."
Dr. Jaecklin added, "The NLRP3 inflammasome is one of the most exciting emerging areas of therapeutic science, and NodThera™s best-in-class molecules hold great potential to address the unmet medical need in multiple neurodegenerative and cardiometabolic diseases. With a wealth of excellent data and two ongoing Phase Ib/IIa studies, I am excited to be joining the Company at such a critical juncture and look forward to working with the leadership team and Board to advance our clinical programs.."
NodThera is currently conducting a Phase Ib/IIa study of its lead candidate, NT-0796, in Parkinson's disease patients, with results expected in the first quarter of 2024. Another Phase Ib/IIa study assessing cardiovascular risk in an inflamed obese population is set to provide results in the second quarter of 2024.
The company, headquartered in Boston with additional operations in the UK and Seattle, is supported by a consortium of top-tier investors. NodThera's clinical candidates are oral, small molecule NLRP3 inflammasome inhibitors that have shown promise in penetrating the brain and exerting anti-inflammatory effects.
This news is based on a press release statement from NodThera.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.